Favezelimab
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research in combination with the PD-L1 inhibitor Pembrolizumab. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)[2].
Product Specifications
CAS Number
2231068-83-8
Product Name Alternative
MK-4280; Mavezelimab
UNSPSC
12352203
Target
LAG-3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/favezelimab.html
Purity
97.79
Solubility
H2O
Smiles
[Favezelimab]
Molecular Weight
(145.98 kDa)
References & Citations
[1]Carmen Belli, et al. Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies. Cancers (Basel) . 2022 Sep 1;14 (17) :4278.|[2]Gareth P. Gregory, et al. Abstract CT106: Anti-LAG-3 antibody MK-4280 in combination with pembrolizumab for the treatment of hematologic malignancies: A Phase I/II study. Cancer Res (2019) 79 (13_Supplement) : CT106.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC880745-100 1x 100 µL
CD45 / LCA (2B11 + PD7/26), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880270-100 1x 100 µL
Fibronectin (HFN7.1), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400806-500 1x 500 µL
TYRP1 (Tyrosinase Related Protein 1) (TA99), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400525-100 1x 100 µL
CD63 (MX-49.129.5), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details